integrilin solution
merck canada inc - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors
integrilin
glaxosmithkline (ireland) limited - eptifibatide - angina, unstable; myocardial infarction - antithrombotic agents - integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ecg changes and / or elevated cardiac enzymes.patients most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (ptca).
integrilin iv bolus injection 2 mgml
msd pharma (singapore) pte. ltd. - eptifibatide - injection - 2 mg/ml - eptifibatide 2 mg/ml
integrilin iv infusion 0.75 mgml
msd pharma (singapore) pte. ltd. - eptifibatide - injection - 0.75 mg/ml - eptifibatide 0.75 mg/ml
integrilin 20mg10ml solution for injection vials
glaxosmithkline uk ltd - eptifibatide - solution for injection - 2mg/1ml
integrilin 75mg100ml solution for infusion vials
glaxosmithkline uk ltd - eptifibatide - solution for infusion - 750microgram/1ml
integrilin
glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml
integrilin
glaxo operations uk ltd. - eptifibatide - solution for injection - 2mg/ml
integrilin 0,75mg/ml solution for infusion
glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml
integrilin 2mg/ml solution for injection
glaxo operations uk ltd. - eptifibatide - solution for injection - 2mg/ml